dc.contributor.author | Derin, Okan | |
dc.contributor.author | Şahin, Meyha | |
dc.contributor.author | Dumlu, Rıdvan | |
dc.contributor.author | Başgönül, Sedef | |
dc.contributor.author | Bayrak, Ahmet Doğukan | |
dc.contributor.author | Arduç, Şevval | |
dc.contributor.author | Bayram, Sümeyye | |
dc.contributor.author | Mikaliyova, Nurlana | |
dc.contributor.author | Kantürk, Arzu | |
dc.contributor.author | Öncül, Ahsen | |
dc.contributor.author | Yıldız Sevgi, Dilek | |
dc.contributor.author | Gençer, Serap | |
dc.contributor.author | Bayraktar, Banu | |
dc.contributor.author | Dökmetaş, İlyas | |
dc.contributor.author | Mert, Ali | |
dc.date.accessioned | 2024-02-02T10:28:12Z | |
dc.date.available | 2024-02-02T10:28:12Z | |
dc.date.issued | 2024 | en_US |
dc.identifier.citation | Derin, O., Şahin, M., Dumlu, R., Başgönül, S., Bayrak, A. D., Arduç, Ş. ... Mert, A. (2024). Registry-based retrospective cohort study of mortality among adults admitted to intensive care units in İstanbul with hospital acquired pseudomonas aeruginosa bloodstream-infection between 2014–2021. Antibiotics, 13(1). https://dx.doi.org/10.3390/antibiotics13010090 | en_US |
dc.identifier.issn | 2079-6382 | |
dc.identifier.uri | https://dx.doi.org/10.3390/antibiotics13010090 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12243 | |
dc.description.abstract | Background: Managing Pseudomonas aeruginosa bloodstream infections (BSIs) is challenging due to increasing antimicrobial resistance, limited therapeutic options, and high mortality rates. In this study, we aimed to identify 30-day mortality risk factors and assess infectious diseases consultants’ preferences for combination or monotherapy. Methods: The study was conducted in four hospitals in Istanbul, Turkey, involving 140 adult ICU beds and 336,780 ICU-bed-days between 1 January 2014, and 31 December 2021. A total of 157 patients were included in the study. Cox proportional hazard regression was performed to assess the factors on 30-day mortality. Results: The 30-day mortality rate was 44.6% (70/157). Higher Charlson Comorbidity Index (CCI) score, severe sepsis, primary bloodstream infection, being in COVID-19 pandemic period, and infection caused by MDR strain were associated with higher hazard of 30-day mortality. Combination therapy was more commonly used in patients with BSIs with MDR or DTR (difficult-to-treat) strains but did not significantly improve the hazard of 30-day mortality. Conclusions: Targeted interventions and vigilant management strategies are crucial for patients with defined risk factors. While infectious disease consultants tended to favor combination therapy, particularly for drug-resistant strains, our analysis revealed no significant impact on 30-day mortality hazard. The increased incidence of P. aeruginosa BSIs during the pandemic emphasizes the need for infection control measures and appropriate antibiotic prescribing practices. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Bloodstream Infections | en_US |
dc.subject | Intensive-Care Units | en_US |
dc.subject | Pseudomonas | en_US |
dc.title | Registry-based retrospective cohort study of mortality among adults admitted to intensive care units in İstanbul with hospital acquired pseudomonas aeruginosa bloodstream-infection between 2014–2021 | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Antibiotics | en_US |
dc.department | İstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Epidemiyoloji Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-6311-5428 | en_US |
dc.authorid | 0000-0003-4147-3587 | en_US |
dc.authorid | 0000-0001-8945-2385 | en_US |
dc.identifier.volume | 13 | en_US |
dc.identifier.issue | 1 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3390/antibiotics13010090 | en_US |
dc.institutionauthor | Derin, Okan | |
dc.institutionauthor | Şahin, Meyha | |
dc.institutionauthor | Mikaliyova, Nurlana | |
dc.institutionauthor | Mert, Ali | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001151767300001 | en_US |
dc.identifier.scopus | 2-s2.0-85183175029 | en_US |
dc.identifier.pmid | 38247649 | en_US |
dc.identifier.scopusquality | Q1 | en_US |